PRODUCTS AND SERVICES

Product Center

Pan-Genomic Testing

  • 422 cancer-related genes fully tested – 100% coverage of all exons & significant introns
  • Minimal sample requirement – a single test covers all currently available molecular-targeted & chemotherapy drugs, and ongoing clinical trials
  • High precision technology with negative control greatly reduces possibility of false positive/negative results when compared with traditional testing methods
  • Can test a wide range of genetic abnormalities including point mutations, fusions, insertions, deletions and amplifications
  • Prompts hereditary risks

Selecting 422 Genes

Carefully Selected: Covers ALL known actionable cancer-related genes

Minimally Invasive: Each test requires just 8ml of peripheral blood*

*We recommend first-time patients to provide existing tissue samples for testing quality control purposes

Minimally-Invasive Pan-Genomic Testing

  • A mere 8ml of peripheral blood is all that is required to establish minimally-invasive monitoring for real-time reporting of cancer progression
  • Over 90% matching rate between ctDNA and regular tumor tissue testing results
  • 416 cancer-related genes fully tested – 100% coverage of all exons & significant introns
  • A single test covers all currently available molecular-targeted & chemotherapy drugs, and ongoing clinical trials
  • Can test a wide range of genetic abnormalities including point mutations, fusions, insertions, deletions and amplifications
  • Prompts hereditary risks

Lung Cancer Testing


百迈康

Pulmocan®

Lung Cancer Testing

100% coverage of all exons and significant introns of 123 lung cancer related genes. Minimal sample requirement. Covers 67 molecular-targeted/chemo drugs and current clinical trials related to lung cancer. Pulmocan is minimally-invasive, supports dynamic monitoring of disease progression, prompts discovery of drug resistance which allows timely adjustments of treatment plans.

点击下载

初得康

Tetradecan®

Lung Cancer Testing

100% coverage of all exons and significant introns of NCCN lung cancer guideline-recommended genes and related core genes of other pathways (14 genes in total). Minimal sample requirement, covers lung cancer related molecular targeted drugs and clinical trials.

点击下载

Gastro-Intestinal Cancer Testing


斯达康

Stomocan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 49 stomach cancer related genes. Stomocan has minimal sample requirement, covers stomach cancer related molecular targeted/chemotherapy drugs and clinical trials, includes MSI testing which prompts stomach cancer prognosis, provides guidance to immunotherapies (PD-1/PD-L1), and prompts hereditary risks.

点击下载

英泰康

Intescan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 45 intestinal cancer related genes. Intescan has minimal sample requirement, covers intestinal cancer related molecular targeted/chemotherapy drugs and clinical trials, includes MSI testing which prompts intestinal cancer prognosis, provides guidance to immunotherapies (PD-1/PD-L1) and post-operative auxiliary chemotherapies, and prompts hereditary risks.

点击下载

利福康

Livocan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 41 liver/gallbladder cancer related genes. Livocan has minimal sample requirement, covers liver/gallbladder cancer related molecular targeted/chemotherapy drugs and clinical trials, and prompts hereditary risks.

点击下载

盼可康

Pancrecan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 40 pancreas cancer related genes. Pancrecan has minimal sample requirement, covers pancreas cancer related molecular targeted/chemotherapy drugs and clinical trials, and prompts hereditary risks.

点击下载

吉士康

Gistcan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 39 genes related to gastro-intestinal stromal tumor (GIST). Gistcan has minimal sample requirement, covers GIST-related molecular targeted/chemotherapy drugs and clinical trials, and prompts hereditary risks.

点击下载

依福康

Esophacan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 53 genes related to esophageal cancer. Esophacan has minimal sample requirement, covers esophageal cancer related molecular targeted/chemotherapy drugs and clinical trials, tests for inactivating mutations of related MSI/MMR genes to comprehensively prompt hereditary risks.

点击下载

Breast Cancer & Gynecological Cancer Testing


汝美康

Mamecan®

Breast Cancer & Gynecological Cancer Testing

100% coverage of all exons and significant introns of 48 breast cancer related genes. Mamecan has minimal sample requirement, covers breast cancer related molecular targeted/endocrinal/chemotherapy drugs and clinical trials, and prompts hereditary risks.

点击下载

汝赛宁

Mamserene®

Breast Cancer & Gynecological Cancer Testing

Breast cancer prognosis & relapse risk assessment through expression of 21 genes. Recommended for patients with invasive breast cancer (lymph node negative or positive, ER positive). Mamserene allows patients to gain a clear understanding of potential risks of disease relapse and expected chemotherapy benefits through the use of quantified indicators. Mamserene is also able to analyze in detail the potential side effects associated with drugs used in post-operative endocrinal therapies.

点击下载

吉诺康

Gynocan®

Breast Cancer & Gynecological Cancer Testing

100% coverage of all exons and significant introns of 50 common gynecological cancer (ovarian/cervical/endometrial) related genes. Gynocan has minimal sample requirement, covers common gynecological cancer related molecular targeted/chemotherapy drugs and clinical trials, covers MSI-guided immunotherapies (PD-1/PD-L1, etc.) and comprehensively prompts hereditary risks.

点击下载

Prostate Cancer & Urological Tumor Testing


普罗康

Proscan®

Prostate Cancer & Urological Tumor Testing

100% coverage of all exons and significant introns of 40 prostate cancer related genes. Proscan has minimal sample requirement, covers prostate cancer related molecular targeted/endocrinal/chemotherapy drugs and clinical trials, covers MSI testing and may be used to guide immunotherapies (PD-1/PD-L1).

点击下载

优罗康

Urocan®

Prostate Cancer & Urological Tumor Testing

100% coverage of all exons and significant introns of 55 common urological tumors (kidney/bladder) related genes. Urocan has minimal sample requirement, covers common gynecological cancer related molecular targeted/chemotherapy drugs and clinical trials, covers MSI testing which may provide guidance to immunotherapies (PD-1/PD-L1, etc.) and comprehensively prompts hereditary risks.

点击下载

Blood-Lymphatic System Disease Testing


血默胜

Hemasalus®

Blood-Lymphatic System Disease Testing

Recommended for patients with malignant neoplasms of the blood-lymphatic system, Hemasalus sequences 390 related DNA and total RNA which may come from a variety of sample types including blood, bone marrow, fresh tissue, FFPE, oral exfoliative cells, etc. Test results can be used to assist in clinical diagnosis of the disease as well as MRD testing, exploration of drug-resistance mechanisms, post-transplantation chimerism testing, ultimately guiding disease treatment enabling prognosis assessment.

点击下载